-
Professor Jun Ma : Continuous Innovation in Drugs Powers the Transition of Cancer into Chronic Disease Management
For cancer patients, prolonged drug therapy, particularly intravenous treatments, can lead to various inconveniences like infusion reactions and phlebitis. The emergence of new formulations of anticancer drugs not only reduces treatment costs and saves time but also brings convenience to both patients and clinicians. In an era where chronic disease management is becoming more prevalent,…
-
EBMT China Voice | Dr. Yishan Ye : Comparative Study of Haploidentical, Sibling Matched, and Unrelated Matched Allogeneic Hematopoietic Stem Cell Transplantation in Core Binding Factor AML Patients in Second Complete Remission (CR2)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a crucial therapeutic option for a variety of benign and malignant hematological diseases. In recent years, the proportion of haploidentical transplants has been increasing due to advancements in the technology. From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting…
-
Professor Xinan Sheng’s Insights on Key Studies in Kidney Cancer at the 2024 ASCO-GU Annual Meeting | ASCO-GU Highlights Reviewed by Key Opinion Leaders
The 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) was held from January 25th to 27th in San Francisco, showcasing the most innovative scientific advancements in the field and discussing future treatment directions for genitourinary cancers. Among them, several groundbreaking studies in the field of kidney cancer were presented, and “Oncology Frontier” invited…
-
Professor Ning Shen’s Team: Mechanism of Resistance to Cefiderocol in Highly Virulent Klebsiella pneumoniae | ESCMID Global 2024
As the global issue of antimicrobial resistance intensifies, newly emerging resistant bacterial strains pose a significant threat to public health. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study by Professor Ning Shen’s team from Peking University Third Hospital (Abstract No.: E0451) focused on the resistance issues of…
-
ASCO GU Researcher Speaks丨Professor St-Laurent: Urinary Tumor DNA Detects Minimal Residual Disease, Aiding in Extended Patient Survival
The ASCO-GU 2024, a major event in the field of urologic oncology, was held in San Francisco, USA, showcasing numerous innovative research advancements and discussing future treatment directions for urologic and male reproductive system tumors. For patients with non-muscle invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin (BCG) treatment, there remains a…
-
EBMT Interview Highlight | Optimizing Outcomes After Transplantation: Updates to International Guidelines
In recent years, advancements in Hematopoietic Cell Transplantation (HCT) technology have significantly improved long-term survival rates, with about 80% of patients achieving disease-free survival for more than two years post-transplant. However, as time progresses, long-term survivors of transplantation still face the risk of chronic complications, which directly impact their quality of life and outcomes post-transplant.…
-
EBMT China Voice | Professor Yue Lu ‘s Team: Clinical Characteristics and Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation Combined with Mucormycosis
Mucormycosis is a group of rare and highly invasive fungal diseases, and its combination with allogeneic hematopoietic stem cell transplantation increases the difficulty of diagnosis and treatment. Previously, the difficulty in rapidly diagnosing mucormycosis often led to poor prognosis in patients with transplantation-associated mucormycosis. At the 50th European Society for Blood and Marrow Transplantation (EBMT)…
-
EBMT Hot Commentary | Professor Jie Jin: Turning the Tide, Extending Survival — Pre-Transplant Salvage Chemotherapy for Relapsed/Refractory AML Based on Venetoclax
Acute myeloid leukemia (AML) is a common and aggressive hematological malignancy with poor prognosis. For patients with relapsed/refractory (R/R) AML, allogeneic hematopoietic stem cell transplantation (allo-SCT) is one of the important treatment options. However, patients with R/R AML often face primary or secondary drug resistance and limited treatment options due to complications and physical condition,…
Connecting Medical Expertise through Media